首页> 外文期刊>Vaccine >Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of Toxoplasma gondii in murine models of experimental toxoplasmosis.
【24h】

Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of Toxoplasma gondii in murine models of experimental toxoplasmosis.

机译:在弓形虫病小鼠模型中评估三种由弓形虫表面抗原和分泌抗原组成的重组多抗原疫苗。

获取原文
获取原文并翻译 | 示例
           

摘要

The great clinical and economical impact of Toxoplasma gondii infections makes the development of an effective vaccine for controlling toxoplasmosis an extremely important aim. In the presented study, we evaluate the protective and immunogenic properties of three recombinant subunit vaccines composed of rROP2+rGRA4+rSAG1, rROP2+rROP4+rGRA4 and rROP2+rROP4+rSAG1 proteins of T. gondii in an experimental toxoplasmosis model in the C3H/HeJ and C57BL/6 mouse strains. All three recombinant vaccines induced partial protection as measured by the reduction of brain cyst burden following challenge with five tissue cysts of the low virulence DX T. gondii strain. The level of protection was dependent on the antigen composition of the vaccine and the genetic background of the laboratory animals. The strongest protection against chronic toxoplasmosis was induced in both C3H/HeJ and C57BL/6 mice by the mixture of rhoptry proteins rROP2 and rROP4 combined with tachyzoite major protein rSAG1. The average parasite burden in these groups of mice was reduced by 71% and 90%, respectively, compared to non-vaccinated mice. The observed protective effect was related to the vaccine-induced cellular and humoral immune responses, as measured by the antigen-induced release of the Th1 cytokines IFN- gamma and IL-2, the antigen-stimulated proliferation of spleen cells of vaccinated animals in comparison to control animals and the development of systemic antigen-specific IgG1 and IgG2a (C3H/HeJ) or IgG2c (C57BL/6) antibodies. Our studies show that recombinant rROP2, rROP4, rGRA4 and rSAG1 antigens may be promising candidates for a subunit vaccine against toxoplasmosis. Additionally, we demonstrate that the ideal composition of vaccine antigens can be equally effective in mice with different genetic backgrounds and variable levels of innate resistance to toxoplasmosis, resulting in strong protection against T. gondii invasion.
机译:弓形虫感染的巨大临床和经济影响使开发有效的控制弓形虫病的疫苗成为极为重要的目标。在本研究中,我们评估了三种重组亚基疫苗的保护和免疫原性,这些疫苗由iT的rROP2 + rGRA4 + rSAG1,rROP2 + rROP4 + rGRA4和rROP2 + rROP4 + rSAG1蛋白组成。弓形虫在C3H / HeJ和C57BL / 6小鼠品系的弓形虫实验模型中。通过用低毒力DX T的五个组织囊肿攻击后脑囊肿负担的减少来测量,所有三种重组疫苗均诱导了部分保护。刚地菌株。保护水平取决于疫苗的抗原组成和实验动物的遗传背景。通过结合rhoPry蛋白rROP2和rROP4与速殖子主要蛋白rSAG1的混合物,在C3H / HeJ和C57BL / 6小鼠中诱导出对慢性弓形虫病的最强保护。与未接种疫苗的小鼠相比,这些组小鼠的平均寄生虫负担分别减少了71%和90%。观察到的保护作用与疫苗诱导的细胞和体液免疫反应有关,如通过抗原诱导的Th1细胞因子IFN-γ和IL-2释放,抗原刺激的免疫接种动物脾脏细胞增殖来衡量以控制动物和全身性抗原特异性IgG1和IgG2a(C3H / HeJ)或IgG2c(C57BL / 6)抗体的发育。我们的研究表明,重组rROP2,rROP4,rGRA4和rSAG1抗原可能是抗弓形虫亚单位疫苗的有前途的候选药物。另外,我们证明了理想的疫苗抗原组成在具有不同遗传背景和可变水平的先天性对弓形虫病抗性的小鼠中可以同样有效,从而对T产生强大的保护作用。刚地入侵。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号